# 500 Class 10: 2023-03-30

[Main Website](https://thomaselove.github.io/500-2023/) | [Calendar](https://thomaselove.github.io/500-2023/calendar.html) | [Syllabus](https://thomaselove.github.io/500-syllabus-2023) | [Canvas](https://canvas.case.edu) | [Data/Code](https://github.com/THOMASELOVE/500-data) |  [Sources](https://github.com/THOMASELOVE/500-classes-2023/tree/main/sources) | For help, email
:-----------: | :--------------: | :----------: | :---------: | :-------------: | :------: | :-----------: 
links for everything | deadlines | expectations | zoom, submissions | downloads | to read | `Thomas` dot `Love` at `case` dot `edu`

## Today's Slides

Class | Date | PDF | Quarto .qmd | Recording
:---: | :--------: | :------: | :------: | :-------------:
10 | 2023-03-30 | **[Slides 10](https://github.com/THOMASELOVE/500-slides-2023/blob/main/500_slides10.pdf)** | **[Code 10](https://github.com/THOMASELOVE/500-slides-2023/blob/main/500_slides10.qmd)** | Visit [Canvas](https://canvas.case.edu/), select **Zoom** and **Cloud Recordings**

## Today's OSIA presentations

First Reader | Second Reader | PDF Links | Citation and DOI Link (to read the Abstract)
:-----------: | :-----------: | :---------: | :-------------------------------------------------------------------------
Peng Zhang | Ife Babatunde | [Wu TD et al 2019](pdf/wu_2019.pdf) | Wu TD et al. (2019) Association of Metformin Initiation and Risk of Asthma Exacerbation: A Claims-based Cohort Study *Ann Am Thorac Soc* 16(12): 1527-33. https://doi.org/10.1513/AnnalsATS.201812-897OC
Zunren (Jack) Liu | Millenia Zhou | [Wu J et al 2022](pdf/wu_2022.pdf) | Wu J et al. (2022) Higher Collective Responsibility, Higher COVID-19 Vaccine Uptake, and Interaction with Vaccine Attitude: Results from Propensity Score Matching *Vaccines* 10: 1295. https://doi.org/10.3390/vaccines10081295
Alise Carlson | Peng Zhang | [Pape et al 2022](pdf/pape_2022.pdf), and [Supplement](pdf/pape_2022_supplement.pdf) | Pape K et al. (2022) Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score–matched study *Ther Adv Neurol Disord* 15: 1-15. https://doi.org/10.1177/17562864221142924

## Today's Rosenbaum Discussion: Chapter 9 (Sensitivity to Bias)

In one of Dr. Love’s papers using matched propensity-score analysis, a significant result was obtained favoring the treatment group over a control, and the calculated sensitivity parameter value was 1.5. Now imagine that you did a study and obtained such a result. Provide a basic description of your imaginary study’s population, outcome, treatment and covariates so we can follow your logic. Provide a description of what that value means in English, and discuss how your reaction to the study and its importance might differ if the significance level was unchanged but the sensitivity parameter had instead been 1.1, or 2.0.


